Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
Volume: 130, Issue: 5, Pages: 2209 - 2219
Published: Mar 23, 2020
Abstract
BACKGROUND. Mirabegron is a β3-adrenergic receptor (β3-AR) agonist approved only for the treatment of overactive bladder. Encouraging preclinical results suggest that β3-AR agonists could also improve obesity-related metabolic disease by increasing brown adipose tissue (BAT) thermogenesis, white adipose tissue (WAT) lipolysis, and insulin...
Paper Details
Title
Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
Published Date
Mar 23, 2020
Volume
130
Issue
5
Pages
2209 - 2219
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History